ArticleFrontiers in pharmacology2026
Exploring the impact of GLP-1 analogues and DPP-4 inhibitors on cognitive decline in elderly patients with type 2 diabetes: a competing risks analysis from a real-world cohort.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Older adults with type 2 diabetes (T2DM) face an increased risk of cognitive decline. While glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown neuroprotective effects, comparative evidence versus dipeptidyl peptidase-4 inhibitors (DPP-4i) in real-world older populations is limited. Methods: We conducted a retrospective cohort study using health administrative data, including individuals aged ≥65 initiating GLP-1RAs or DPP-4i therapy between 2010 and 2018. Patients with prior cognitive disorders were excluded. The primary outcome was a composite of incident cognitive disorders or death. Analyses were adjusted for clinical and demographic characteristics. Marginal structural models and competing risks methods were used to estimate treatment effects. Both an 'As treated' (AT) and an 'Intention to Treat' (ITT) designs were employed. Results: A total of 2,579 individuals were included (GLP-1RAs: 393; DPP-4i: 2,186), with a median follow-up of 44 months in the AT analysis. GLP-1RAs users had a lower risk of the composite outcome, especially in the early follow-up (HR at 2 years: 0.5 [95% CI: 0.26-0.93]). Competing-risk analysis showed a lower early risk of death without prior cognitive disorders among GLP-1RA initiators. The point estimate of sub-distribution HR was 0.4 also for cognitive disorders, yet not statistically significant because of the small number of events. Conclusion: GLP-1RAs use was associated with a lower early risk of the composite outcome of cognitive disorders or death compared with DPP-4i in older adults with T2DM. The observed association with cognitive disorders alone was directionally consistent with a potentially lower risk, but the very small number of events precludes firm conclusions regarding a protective effect on cognitive outcomes. Longer follow-up and cognitive-specific evaluations are needed to confirm these associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.